A PHASE 1B/2 STUDY EVALUATING THE SAFETY AND EFFICACY OF NANATINOSTAT PLUS VALGANCICLOVIR FOR TREATMENT OF RELAPSED/REFRACTORY EPSTEIN-BARR VIRUS-POSITIVE NODAL PERIPHERAL T-CELL LYMPHOMA
a Division of Hematology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, Brazil
b Division of Hematology, A Beneficência Portuguesa de São Paulo (BP), São Paulo, Brazil
c Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil
d Division of Hematologic Malignancies and Hematopoetic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, United States
e Applied Statistics and Consulting, Spruce Pine, United States
f Viracta Therapeutics, Inc., Cardiff, United States
g Division of Hematology, University of Colorado, Denver, United States
Lido
1265
Vezesque se leu este artigo
480
Total PDF
785
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 10 | 43 | 19 | 62 |
| 2025 9 | 48 | 28 | 76 |
| 2025 8 | 33 | 24 | 57 |
| 2025 7 | 50 | 25 | 75 |
| 2025 6 | 39 | 16 | 55 |
| 2025 5 | 46 | 13 | 59 |
| 2025 4 | 36 | 15 | 51 |
| 2025 3 | 45 | 11 | 56 |
| 2025 2 | 34 | 14 | 48 |
| 2025 1 | 35 | 27 | 62 |
| 2024 12 | 17 | 11 | 28 |
| 2024 11 | 29 | 18 | 47 |
| 2024 10 | 39 | 25 | 64 |
| 2024 9 | 38 | 19 | 57 |
| 2024 8 | 34 | 24 | 58 |
| 2024 7 | 34 | 26 | 60 |
| 2024 6 | 35 | 25 | 60 |
| 2024 5 | 45 | 25 | 70 |
| 2024 4 | 28 | 10 | 38 |
| 2024 3 | 26 | 24 | 50 |
| 2024 2 | 14 | 21 | 35 |
| 2024 1 | 12 | 14 | 26 |
| 2023 12 | 13 | 24 | 37 |
| 2023 11 | 10 | 15 | 25 |
| 2023 10 | 2 | 7 | 9 |
Mostrar tudo
